Active Volume Stock Update: Sorrento Therapeutics inc (NASDAQ:SRNE)


Sorrento Therapeutics inc (NASDAQ:SRNE) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Buy” signal. 10 – 8 Day Moving Average Hilo Channel shows “Buy” signal. While 20-Day Moving Average VS Current Price shows “Buy” Signal.

Sorrento Therapeutics inc (NASDAQ:SRNE) gained 4.17 Percent and closed its previous trading session at $7.5. The stock traded with the average Volume of 2.08 Million at the end of last session.

Sorrento Therapeutics inc (NASDAQ:SRNE) has the Market Capitalization of 904.43 Million. The Stock has its 52-week High of $10.65 and 52-Week Low of $ 1.50 and it touched its 52-week high on 03/01/18 and 52-Week Low on 08/24/17


The company reported its last earnings Actual EPS of $-0.38/share. While, the analyst predicted that the company could provide an EPS of $-0.17/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.21/share which shows an Earnings Surprise of -123.5 Percent.

Sell side analysts plays vital role in buying and selling a stock where 2 analysts rated Sorrento Therapeutics inc (NASDAQ:SRNE) as Buy, 0 analysts given Outperform signal, 0 reported Hold, and 0 analysts rated the stock as Sell.

The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 7.57% where SMA50 and SMA200 are 4.56% and 37.5% respectively.

The company shows its Return on Assets (ROA) value of -0.1%. The Return on Equity (ROE) value stands at -0.2%. While it’s Return on Investment (ROI) value is 27.4%.

Sorrento Therapeutics inc (NASDAQ:SRNE) currently has a Weekly Volatility of 5.86% percent while its Monthly Volatility is at 7.96% percent. While talking about Performance of the Stock, Sorrento Therapeutics inc currently has a Weekly performance of 14.5%, monthly performance percentage is 3.45 percent, Quarterly performance is 19.05 percent, 6 months performance shows a percent value of 60.43% and Yearly Performance is 284.62 percent.

Company Profile:

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and infectious disease. Sorrento Therapeutics, Inc. is based in San Diego, California.